This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Our extensive oncology clinical trial programme has produced two approved drugs, as well as several other investigational compounds that are currently being investigated across a broad range of tumour types. Find out more below.
| Compound | Target | Focus area | Development stage | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||
|
Afatinib |
|
|
|||||||||
|
Nintedanib |
|
|
|||||||||
|
Xentuzumab |
|
|
|||||||||
|
BI 836858 |
|
|
|||||||||
|
BI 836880 |
|
|
|||||||||
|
BI 1361849 |
|
|
|||||||||
|
BI 894999 |
|
|
|||||||||
|
BI 754091 |
|
|
|||||||||
|
BI 754091 / BI 754111 |
|
|
|||||||||
|
BI 754091 / BI 891065 |
|
|
|||||||||
Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
Xentuzumab, BI 836858, BI 836880, BI 1361849, BI894999, BI 754091, BI 754111 and BI 891065 are investigational compounds and have not been approved. Their safety and efficacy have not been established.
Ang-2, angiopoietin-2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; iv, intravenous; LAG3, lymphocyte activation gene 3 protein; MAGE, melanoma-associated antigen; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; MUC1, mucin 1, cell surface associated; NBE, new biological entity; NCE, new chemical entity; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death protein 1; po, orally; PDGFR, platelet-derived growth factor receptor; SMAC, second mitochondria-derived activator of caspase; TPBG, trophoblast glycoprotein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.